Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
1.87M
-
Shares change
-
+296K
-
Total reported value, excl. options
-
$7.04M
-
Value change
-
+$1.14M
-
Put/Call ratio
-
0.72
-
Number of buys
-
14
-
Number of sells
-
-9
-
Price
-
$3.77
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q1 2024
33 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q1 2024.
Gain Therapeutics, Inc. - COM (GANX) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.87M shares
.
Largest 10 shareholders include DME Capital Management, LP (566K shares), RAYMOND JAMES & ASSOCIATES (260K shares), Royal Bank of Canada (249K shares), GEODE CAPITAL MANAGEMENT, LLC (177K shares), VANGUARD GROUP INC (119K shares), CM Management, LLC (90K shares), BlackRock Inc. (75.4K shares), RENAISSANCE TECHNOLOGIES LLC (46.7K shares), NORTHERN TRUST CORP (46.5K shares), and MILLENNIUM MANAGEMENT LLC (44.4K shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.